Lexaria Bioscience(LEXX.US)

Last Updated 19:00:00 ET
longbridge loading

Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7 | LEXX Stock News

StockTitan·
US
LEXX
+0.73%
US
VHT
+0.27%
US
XBI
+3.88%
StockTitan·
US
LEXX
+0.73%
US
VHT
+0.27%
US
XBI
+3.88%

Lexaria Updates Progress on Human Study #7 | LEXX Stock News

StockTitan·
US
LEXX
+0.73%
US
BBH
+0.96%
US
LABU
+11.76%
StockTitan·
US
LEXX
+0.73%
US
BBH
+0.96%
US
LABU
+11.76%

Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications | LEXX Stock News

StockTitan·
US
LEXX
+0.73%
US
LABU
+11.76%
US
XLV
-0.13%
StockTitan·
US
LEXX
+0.73%
US
LABU
+11.76%
US
XLV
-0.13%

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended | LEXX Stock News

StockTitan·
US
LEXX
+0.73%
US
LABU
+11.76%
US
IBB
+2.27%
StockTitan·
US
LEXX
+0.73%
US
LABU
+11.76%
US
IBB
+2.27%

Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs | LEXX Stock News

StockTitan·
US
LEXX
+0.73%
US
IBB
+2.27%
US
PBE
+1.60%
StockTitan·
US
LEXX
+0.73%
US
IBB
+2.27%
US
PBE
+1.60%

Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales | LEXX Stock News

StockTitan·
US
LEXX
+0.73%
US
SBIO
+3.75%
US
LABU
+11.76%
StockTitan·
US
LEXX
+0.73%
US
SBIO
+3.75%
US
LABU
+11.76%
© 2026 Longbridge｜Disclaimer